Frank T. Watkins Sells 3,000 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV) Stock

Shockwave Medical, Inc. (NASDAQ:SWAVGet Rating) Director Frank T. Watkins sold 3,000 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $278.32, for a total value of $834,960.00. Following the completion of the transaction, the director now directly owns 3,796 shares of the company’s stock, valued at approximately $1,056,502.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shockwave Medical Price Performance

Shares of SWAV opened at $281.50 on Thursday. Shockwave Medical, Inc. has a 12-month low of $154.45 and a 12-month high of $320.54. The business’s fifty day moving average is $255.34 and its 200 day moving average is $226.43. The company has a quick ratio of 3.57, a current ratio of 4.16 and a debt-to-equity ratio of 0.04. The stock has a market cap of $10.30 billion, a P/E ratio of 44.40, a P/E/G ratio of 24.97 and a beta of 0.99.

Shockwave Medical (NASDAQ:SWAVGet Rating) last released its quarterly earnings results on Monday, May 8th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.22. Shockwave Medical had a return on equity of 55.22% and a net margin of 43.18%. The business had revenue of $161.10 million during the quarter, compared to analyst estimates of $147.30 million. During the same period in the prior year, the firm posted $0.39 EPS. Shockwave Medical’s quarterly revenue was up 72.1% compared to the same quarter last year. Sell-side analysts anticipate that Shockwave Medical, Inc. will post 4.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Shockwave Medical

Several large investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of Shockwave Medical by 2.0% during the 3rd quarter. BlackRock Inc. now owns 4,400,318 shares of the company’s stock valued at $1,223,596,000 after purchasing an additional 86,765 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Shockwave Medical by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,531,285 shares of the company’s stock worth $981,946,000 after acquiring an additional 13,619 shares during the period. Invesco Ltd. grew its stake in shares of Shockwave Medical by 16.0% during the 1st quarter. Invesco Ltd. now owns 1,398,211 shares of the company’s stock worth $289,933,000 after acquiring an additional 192,525 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Shockwave Medical by 37.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,394,767 shares of the company’s stock worth $302,428,000 after acquiring an additional 382,374 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Shockwave Medical by 57.9% during the 1st quarter. JPMorgan Chase & Co. now owns 1,273,747 shares of the company’s stock worth $276,185,000 after acquiring an additional 467,237 shares during the period. 90.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SWAV. Deutsche Bank Aktiengesellschaft boosted their target price on Shockwave Medical from $285.00 to $310.00 in a research note on Tuesday, May 9th. Wells Fargo & Company upped their price objective on Shockwave Medical from $252.00 to $275.00 in a research note on Tuesday, May 9th. Canaccord Genuity Group upped their price objective on Shockwave Medical from $247.00 to $252.00 and gave the company a “buy” rating in a research note on Friday, February 17th. TheStreet raised Shockwave Medical from a “c” rating to a “b-” rating in a research note on Friday, March 10th. Finally, Bank of America upped their price objective on Shockwave Medical from $235.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, April 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $266.33.

Shockwave Medical Company Profile

(Get Rating)

Shockwave Medical, Inc operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease.

See Also

Insider Buying and Selling by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.